The combination of plasmid interleukin-12 with a single DNA vaccine is more effective than Mycobacterium bovis (bacille Calmette-Guerin) in protecting against systemic Mycobacterim avium infection
- 1 June 2003
- journal article
- Published by Wiley in Immunology
- Vol. 109 (2) , 308-314
- https://doi.org/10.1046/j.1365-2567.2003.01660.x
Abstract
Sub-unit vaccines utilizing purified mycobacterial proteins or DNA vaccines induce partial protection against mycobacterial infections. For example, immunization with DNA vaccines expressing the gene for the immunodominant 35000 MW protein, common to Mycobacterium avium and Mycobacterium leprae but absent from the Mycobacterium tuberculosis complex, conferred significant protection against infection with either virulent M. avium or M. leprae in mice. However, the level of protection was equivalent to that obtained with the viable, attenuated vaccine, Mycobacterium bovis, bacille Calmette-Guèrin (BCG). The cytokine, interleukin (IL)-12, is essential for priming naïve CD4+ T lymphocytes to differentiate into interferon-gamma (IFN-gamma)-secreting T cells. We have used a novel self-splicing vector expressing both chains of murine IL-12 to determine if plasmid IL-12 would increase the efficacy of a vaccine expressing the M. avium 35000 MW protein (DNA-Av35). Co-immunization with p2AIL-12 and DNA-Av35 led to a significant increase in the number of antigen-specific IFN-gamma secreting cells and total amount of IFN-gamma released, but a concomitant fall in the antibody response to the 35000 MW protein. This pattern of response was associated with enhanced clearance of M. avium from the liver and spleen of coimmunized mice, and was significantly more effective than BCG or DNA-Av35. alone. Following M. avium challenge there was significant increase in the expansion of the 35000 MW antigen-reactive T cells in the coimmunized mice. Therefore, plasmid-delivered IL-12 acts as an effective adjuvant to increase the protective efficacy of a single DNA vaccine against M. avium infection above that achieved by BCG, and this strategy may improve the efficacy of subunit vaccines against M. leprae and M. tuberculosis.Keywords
This publication has 35 references indexed in Scilit:
- Comparative affects of plasmid‐encoded interleukin 12 and interleukin 18 on the protective efficacy of DNA vaccination against Mycobacterium tuberculosisImmunology & Cell Biology, 2002
- Genetic Dissection of Immunity to Mycobacteria: The Human ModelAnnual Review of Immunology, 2002
- Interleukin-12 primes CD4+ T cells for interferon-gamma production and protective immunity during Mycobacterium avium infectionImmunology, 2001
- Induction of in vivo resistance to Mycobacterium avium infection by intramuscular injection with DNA encoding interleukin‐18Immunology, 2001
- Effects of Interleukin-12 in the Long-term Protection Conferred by a Mycobacterium avium Subunit Vaccine . FRONTLINESScandinavian Journal of Immunology, 2000
- Protection against VirulentMycobacterium aviumInfection following DNA Vaccination with the 35-Kilodalton Antigen Is Accompanied by Induction of Gamma Interferon-Secreting CD4+T CellsInfection and Immunity, 2000
- DNA Vaccines: Immunology, Application, and OptimizationAnnual Review of Immunology, 2000
- Impacts of interleukin-12 on multiplication of Mycobacterium tuberculosis and Mycobacterium avium complex in miceClinical Microbiology & Infection, 1999
- Interleukin (IL)-12 Deficiency in Susceptible Mice Infected with Mycobacterium avium and Amelioration of Established Infection by IL-12 Replacement TherapyThe Journal of Infectious Diseases, 1996
- The Adjuvant Effect of Interleukin-12 in a Vaccine Against Leishmania majorScience, 1994